Key Highlights

  • Venture Life acquired FemiClear and CUROXEN for up to $28.0 million, funded entirely from existing cash.
  • The deal gives the group retail access to Walmart, Walgreens, CVS and Target in the US feminine-health market.
  • Group Revenue for the 17 months to 31 May 2026 reached £50.0 million, up 30.9%, with proforma growth of 16.0%.
  • FemiClear/CUROXEN net revenue grew 29.1% to $12.1 million in the twelve months to 31 March 2026.
  • The deal was priced at under two times expected 2026 net revenue, with no new Debt or Equity raised.

LSE-listed consumer self-care group Venture Life has completed a deal worth up to $28 million for two US intimate-health brands, marking its first material Acquisition on American soil since its recent run of UK and European deal-making.

Venture Life Group (LSE:VLG), the LSE-quoted maker of self-care brands such as Balance Activ, Lift and Earol, has struck its first sizeable move into the United States, agreeing to buy the FemiClear and CUROXEN brands from Austin, Texas-based OrganiCare Nature's Sciences for up to $28.0 million. The deal, announced 3 June 2026, extends the group's women's health Franchise across the Atlantic and gives it a retail foothold with Walmart, Walgreens, CVS and Target.

For a company that has spent the past couple of years reshaping its portfolio around a handful of "Power Brands," the deal is the clearest signal yet that management sees international expansion, not further UK bolt-ons, as the next leg of growth.

What Happened

Venture Life signed a sale and purchase agreement on 2 June 2026 to acquire FemiClear and CUROXEN from OrganiCare Nature's Sciences LLC, a Business founded in 2016 by Caroline Goodner. The total consideration is up to $28.0 million: an initial $23.0 million cash payment on completion, deferred consideration of up to $4.0 million contingent on the brands hitting 2026 trading targets, and a further earnout of up to $1.0 million for significant outperformance. The purchase was funded entirely from existing cash, with no new debt or equity raised.

FemiClear, which accounts for roughly 98% of the acquired business's performance, treats bacterial vaginosis, genital herpes, thrush, urinary tract infections and broader vaginal health. CUROXEN is a smaller infection-prevention line for wounds and mouth sores. Five OrganiCare employees and one contractor are transferring to Venture Life, and Goodner will stay on as a consultant, with OrganiCare Manufacturing the products for up to 18 months while production migrates to a third-party contractor.

The 30 June 2026 trading update confirmed completion, noting a £17.5 million Cash Advance for the deal — broadly consistent with the $23.0 million upfront payment once converted from sterling.

Why It Matters

Venture Life's existing women's health business, built around Balance Activ, has been one of its fastest-growing categories in the UK and Europe. FemiClear gives the group an established, branded presence in the far larger US feminine-care market at a stroke, rather than a slow, costly build-out of retail relationships from scratch. Management points to the roughly $0.7 billion US feminine-treatment retail market as the opportunity, and to FemiClear's position as, in chief executive Jerry Randall's words, the "clear No.2" player in that category.

The deal complements the group's existing gynaecological offering and opens a US retail channel it lacked before. It also tests whether Venture Life's playbook of acquiring niche, founder-led consumer-health brands and scaling them through its own infrastructure travels beyond its home markets.

Latest Financial and Operational Performance

Venture Life has recently changed its financial year end, moving from 31 December to 31 May, producing a run of transitional reporting periods. Results for the twelve months to 31 December 2025, published as "interim results" on 31 March 2026 ahead of the changeover, showed revenue of £35.2 million, up 32.2% on 2024's £26.6 million, with proforma growth of 11.4%, though gross Margin edged down to 45.0% from 45.8%. The group swung to a statutory operating loss of £1.3 million (2024: profit of £1.5 million), while adjusted EBITDA was broadly flat at £6.0 million, a 16.9% margin. Profit after tax was £6.1 million, aided by disposal gains, and the group closed the period with £34.2 million of cash and an undrawn £50 million Credit Facility .

The subsequent trading update, covering the full 17-month period to 31 May 2026, reported revenue of £50.0 million, up 30.9%, with proforma growth of 16.0%. Power Brands revenue reached £46.7 million. Net cash fell to £12.0 million at 31 May 2026 from £34.2 million at end-December, reflecting the £17.5 million advance for the FemiClear/CUROXEN deal, while EBITDA was said to be in line with market guidance.

Key Numbers

  • Acquisition consideration: up to $28.0m ($23.0m cash, up to $4.0m deferred, up to $1.0m earnout)
  • FemiClear/CUROXEN net revenue (12 months to 31 March 2026): $12.1m, up 29.1% year-on-year
  • Deal multiples: 1.9x expected 2026 net revenue; 6.1x contribution
  • Group revenue, 17 months to 31 May 2026: £50.0m (+30.9%); proforma growth 16.0%
  • Group revenue, 12 months to 31 December 2025: £35.2m (+32.2%); adjusted EBITDA £6.0m
  • Net cash at 31 May 2026: £12.0m (down from £34.2m at 31 December 2025)
  • Total voting rights (31 July 2026): 120,432,702 shares

Growth Opportunities

The immediate opportunity is scaling FemiClear and CUROXEN through Venture Life's existing infrastructure, with management flagging synergies from 2027 as cross-selling and manufacturing integration take hold. In the UK and Europe, the core Power Brands — Balance Activ, Lift, Glucogel, Earol and Health & Her/Him — continue growing ahead of the wider self-care market, with Health & Her/Him up 44.1% proforma in the 2025 results. The board has also flagged appetite for further " Earnings enhancing" M&A in UK and US markets.

Risks Investors Should Know

Integrating a US acquisition brings execution risk, including the 18-month transition of manufacturing away from OrganiCare, staff retention, and currency exposure from a dollar-denominated business inside a sterling-reporting group. The deferred and earnout consideration depends on 2026 trading targets, which are not guaranteed. The recent fiscal year-end change adds reporting complexity that makes like-for-like comparisons harder to interpret. Venture Life also operates in a competitive market against larger, better-resourced players, and its 2025 results showed a statutory operating loss even as adjusted metrics improved — a gap worth watching.

What to Watch Next

Investors should watch for the group's first full results incorporating FemiClear and CUROXEN, once the transitional reporting cycle settles into a normal 31 May year-end. Progress migrating manufacturing away from OrganiCare, retail sell-through at its four US retailers, and any further acquisitions will indicate whether the expansion is delivering.

Outlook

The FemiClear and CUROXEN deal is modest in absolute terms but a significant strategic step for Venture Life, giving it established US retail presence in a large intimate-health market rather than a slower organic build. Funded from cash and priced at under two times revenue, the Financial Risk looks contained; the bigger question is execution — whether the group can replicate in America the discipline that has driven growth in its UK and European Power Brands.